The ClarIDHy is a multicenter, randomized phase III trial, evaluating the activity of the IDH1 inhibitor ivosidenib compared with placebo in patients with IDH1 mutant CCA that progressed to a previous line of therapy [23,24]. Here, IDH1 is linked to cholangiocarcinoma.